Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - diphtheria toxoid; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; human poliovirus type 3 inactivated; haemophilus influenzae type b polysaccharide protein conjugate - powder and suspension for suspension for injection

Irlande - anglais - HPRA (Health Products Regulatory Authority)

provita eurotech ireland limited - lactobacillus acidophilus la 101; lactobacillus acidophilus la 107; enterococcus faecium sf 101 - oral suspension - antidiarrheals, intestinal anti-inflammatory/antiinfective agents

Irlande - anglais - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - conjugate of haemophilus influenzae type b capsular polysaccharide (polyribosylribitol phosphate) and tetanus; conjugate of neisseria meningitides c capsular polysaccharide and tetanus toxoid (mean tt/ps ratio :1) - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with meningococcus c, conjugated

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - neisseria meningitidis group c strain c11 capsular polysaccharide tetanus toxoid conjugate; haemophilus influenzae type b polysaccharide tetanus toxoid conjugate - powder and solvent for solution for injection

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

performance products inc - bifidobacterium longum; bifidobacterium thermophilum; enterococcus faecium; lactobacillus acidophilus; saccharomyces cerevisiae - oral powder, pre-mix - bifidobacterium longum biological-organism active 0.0 u; bifidobacterium thermophilum biological-organism active 0.0 u; enterococcus faecium biological-organism active 0.0 u; lactobacillus acidophilus biological-organism active 0.0 u; saccharomyces cerevisiae biological-organism active 0.0 u - nutrition & metabolism - calf - up to 12 weeks old | bovine - feed additive

États-Unis - anglais - NLM (National Library of Medicine)

merck sharp & dohme llc - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen (unii: luy6p8763w) (haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen - unii:luy6p8763w) - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen 7.5 ug in 0.5 ml - liquid pedvaxhib is indicated for routine vaccination against invasive disease caused by haemophilus influenzae type b in infants and children 2 to 71 months of age. liquid pedvaxhib will not protect against disease caused by haemophilus influenzae other than type b or against other microorganisms that cause invasive disease such as meningitis or sepsis. as with any vaccine, vaccination with liquid pedvaxhib may not result in a protective antibody response in all individuals given the vaccine. because of the potential for immune tolerance, liquid pedvaxhib is not recommended for use in infants younger than 6 weeks of age. (see precautions.) infants completing the primary two-dose regimen before 12 months of age should receive a booster dose (see dosage and administration). hypersensitivity to any component of the vaccine or the diluent. persons who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: xanthan gum; hypromellose; silicon dioxide; saccharin sodium; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; flavour - amoklavin duo 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoklavin duo 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoklavin duo 400/57, should not require the addition of another antibiotic due to the amoxicillin content of amoklavin duo 400/57.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: saccharin sodium; xanthan gum; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; silicon dioxide; hypromellose; flavour - deva-amoxyclav 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to deva-amoxyclav 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to deva-amoxyclav 400/57, should not require the addition of another antibiotic due to the amoxicillin content of deva-amoxyclav 400/57.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - potassium clavulanate, quantity: 13.58 mg/ml (equivalent: clavulanic acid, qty 11.4 mg/ml); amoxicillin trihydrate, quantity: 91.84 mg/ml (equivalent: amoxicillin, qty 80 mg/ml) - suspension, powder for - excipient ingredients: citric acid; guar gum; sodium citrate; purified talc; aspartame; silicon dioxide; flavour - short-term treatment of the following bacterial infections when caused by sensitive organisms: skin and skin structure infections; urinary tract infections (complicated and uncomplicated); upper respiratory tract infections including sinusitis and otitis media; lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam duo 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam duo 400/57 should not require the addition of another antibiotic due to the amoxycillin content of curam duo 400/57.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - erythromycin lactobionate, quantity: 1.49 g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin panpharma (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin and skin structure infections caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment).,? diphtheria - as an adjunct to diphtheria antitoxin in infections due to corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers.,? acute pelvic inflammatory disease caused by neisseria gonorrhoeae: erythromycin panpharma (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin.,? before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for t. pallidum (by immuno-fluorescence or dark field) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter.,? legionnaires' disease caused by legionella pneumophila. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease.